R^{12} is selected from the group consisting of halogen, C_{3-5} cycloalkyl and C_{1-3} alkyl;
A^3 is C-R^7 or N;
R^7 is selected from the group consisting of -H, halogen and C_{1-5} alkyl;
A^4 is C-R^8 or N;
R^8 is selected from the group consisting of -H, halogen, C_{3-5} cycloalkyl, C_{1-5} alkyl optionally substituted with one or more F, C_{1-5} alkoxy, and -CN;
A^5 is C-R^9 or N;
R^9 is -H or halogen;

with the proviso that the compound is not

N-[1-(3,5-Difluorophenyl)cyclopropyl]-β-methyl-1*H*-imidazole-1-propanamide;
N-[1-(3-Chlorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide;
N-[1-(3-Fluorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide; or
3-Fluoro-N-[1-(3-fluorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide.

In another example, the present disclosure provides a pharmaceutical composition comprising a compound as described herein.

In another example, the present disclosure provides a compound as described herein for use as a medicament.

In another aspect, the present disclosure provides a compound as disclosed herein for use in therapy.

In another example, the present disclosure provides a compound as described herein for use in a method of modulating the activity of a K_v7 channel in a subject, the method comprising administering an effective amount of the compound to the subject.

In another example, the present disclosure provides a compound as described herein for use in a method of modulating the activity of a $K_v7.2$/ $K_v7.3$ channel in a subject, the method comprising administering an effective amount of the compound to the subject.

In another example, the present disclosure provides a compound as described herein for use in the treatment of epilepsy or pain.


In another aspect, the present disclosure provides use of a compound as disclosed herein in the manufacture of a medicament for increasing the activity of a $K_v7.2/K_v7.3$ heteromeric channel in a subject, or the treatment, prevention or alleviation of epilepsy or pain in a subject.

Definitions

The term “alkyl” as used herein refers to a linear or branched hydrocarbon moiety.

Claims

1. A compound according to formula (I):



formula (I)

or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof; or a pharmaceutically acceptable salt thereof;

wherein,

R^0 is selected from the group consisting of -OH, and $-CH_3$;


R^1 is aryl optionally substituted with one or more, identical or different, substituents R^4, or heteroaryl optionally substituted with one or more, identical or different, substituents R^4;

R^4 is selected from the group consisting of C_{1-5} alkyl optionally substituted with one or more F, C_{1-5} alkoxy, halogen and CN;

R^2 is selected from the group consisting of -H, $-CH_3$, and $-CF_3$;

R^3 is selected from the group consisting of –H and -OH;

A is of formula (II):



formula (II)

wherein

A^1 is C-R^5 or N;

R^5 is -H or halogen;

A^2 is C-R^6;


R^6 is selected from the group consisting of C_{1-5} alkoxy optionally substituted with one or more F; C_{1-5} alkyl optionally substituted with one or more F; halogen; and $N(R^{10})(R^{11})$;

R^{10} is C_{1-5} alkyl optionally substituted with one or more, identical or different, substituents R^{12};

R^{11} is -H;


R^{12} is selected from the group consisting of halogen, C_{3-5} cycloalkyl and C_{1-3} alkyl;
A^3 is C-R^7 or N;
R^7 is selected from the group consisting of -H, halogen and C_{1-5} alkyl;
A^4 is C-R^8 or N;
R^8 is selected from the group consisting of -H, halogen, C_{3-5} cycloalkyl, C_{1-5} alkyl optionally substituted with one or more F, C_{1-5} alkoxy, and -CN;
A^5 is C-R^9 or N;
R^9 is -H or halogen;
with the proviso that the compound is not
N-[1-(3,5-Difluorophenyl)cyclopropyl]-β-methyl-1*H*-imidazole-1-propanamide;
N-[1-(3-Chlorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide;
N-[1-(3-Fluorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide; or
3-Fluoro-N-[1-(3-fluorophenyl)cyclopropyl]-β-hydroxybenzenepropanamide.

2. The compound according to claim 1, wherein the compound is of formula (IIIa):



formula (IIIa)

or wherein the compound is of formula (IIIb):



formula (IIIb)


3. The compound according to any one of the preceding claims, wherein R^1 is phenyl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, thiazol-2-yl or thiazol-5-yl

optionally substituted with one or more, identical or different substituents R^4 selected from the group consisting of -F, -Cl, -Br, C_{1-5} alkoxy, C_{1-5} alkyl, and -CN.

4. The compound according to claim 1 or 2, wherein R^1 is phenyl substituted with one or more, identical or different, substituents R^4 selected from the group consisting of -F, -Cl, -Br, C_{1-5} alkoxy, C_{1-5} alkyl, and -CN, optionally wherein R^1 is phenyl substituted with one or more -F; or wherein R^1 is indolyl substituted with one or more, identical or different substituents R^4 selected from the group consisting of -F, -Cl, -Br, and C_{1-5} alkyl.

5. The compound according to claim 1 or 2, wherein R^1 is pyridinyl substituted with one or more, identical or different, substituents R^4 selected from the group consisting of -F, -Cl, -Br, C_{1-5} alkoxy, C_{1-5} alkyl, and -CN, or wherein R^1 is thiazolyl substituted with one or more, identical or different substituents R^4 selected from the group consisting of -F, -Cl, -Br, and C_{1-5} alkyl.


6. The compound according to claim 1 or 2, wherein R^1 is selected from:



and .

7. The compound according to any one of the preceding claims, wherein R^2 is $-CH_3$ and R^0 is -OH, optionally wherein R^3 is -H; or wherein R^2 is $-CF_3$ and R^0 is -OH, optionally wherein R^3 is -H.

8. The compound according to any one of the preceding claims, wherein A is of formula (II),



formula (II)

wherein:

a) A^1 is C-R^5; A^2 is C-R^6; A^3 is C-R^7; A^4 is C-R^8; and A^5 is C-R^9, or

b) A^1 is N; A^2 is C-R^6; A^3 is C-R^7; A^4 is C-R^8; and A^5 is C-R^9, or


c) A^1 is C-R^5; A^2 is C-R^6; A^3 is N; A^4 is C-R^8; and A^5 is C-R^9, or

d) A^1 is C-R^5; A^2 is C-R^6; A^3 is C-R^7; A^4 is N; and A^5 is C-R^9, or

e) A^1 is N; A^2 is C-R^6; A^3 is N; A^4 is C-R^8; and A^5 is C-R^9, or

f) A^1 is C-R^5; A^2 is C-R^6; A^3 is C-R^7; A^4 is C-R^8; and A^5 is N.
















9. The compound according to any one of the preceding claims, wherein

- R^5 is -H or -F,
- R^6 is -CF_3, -Cl, -Br, -CH_3 -OCH_2CF_3, -OCF_3, -OCH_3, -OCH_2CF_2H, –OCF_2H, -N(H)(CH_2CF_3), , -N(H)$CH_2C(CH_3)_3$, or -N(H)C(H)$(CH_3)_2$,
- R^7 is -H, -Cl, -F or -CH_3,
- R^8 is -H, -F, -Cl, - Br, –CN, –CF_2H, cyclopropyl, or -OCH_3.
- R^9 is -H or -F.

10. The compound according to any one of the preceding claims, wherein A^1 is C(H), A^2 is C(OCH_2CF_3) and A^5 is C(H) or wherein A^1 is N, A^3 is C(H) and A^5 is C(H).

11. The compound according to any one of the preceding claims, wherein at least one of A^1, A^3 and A^4 is not -C(H).

















12. The compound according to any one of claims 1 to 11, wherein A is selected from:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and

.

13. The compound according to claim 1, wherein the compound is (R)-3-(6-chloropyridin-3-yl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(R)-3-(5-fluoropyridin-2-yl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)-butanamide,
(R)-3-hydroxy-3-(2-methoxypyridin-4-yl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-3-(2,4-difluorophenyl)-N-(1-(4-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)-3-hydroxybutanamide,
(R)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-butanamide,
(R)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(trifluoromethoxy)phenyl)cyclopropyl) butanamide,
(R)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(2-(2,2,2-trifluoroethoxy)pyridin-4-yl)cyclopropyl)butanamide,
(R)-3-hydroxy-3-(p-tolyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(R)-3-(4-cyanophenyl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)-butanamide,
(R)-3-(2,4-difluorophenyl)-N-(1-(2-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)-3-hydroxybutanamide,
(R)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(4-methyl-3-(2,2,2-trifluoroethoxy)-phenyl)cyclopropyl)butanamide,
(R)-N-(1-(3-chloro-5-(difluoromethyl)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-3-(3,5-difluorophenyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-butanamide,
(R)-4,4,4-trifluoro-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)-phenyl)cyclopropyl)butanamide,
(R)-N-(1-(3-bromophenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-cyano-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(4-fluorophenyl)-3-hydroxybutanamide,

(R)-(3-(2,4-difluorophenyl)-N-(1-(3-fluoro-5-(2,2,2-trifluoroethoxy)-phenyl)cyclopropyl)-3-hydroxybutanamide,
(R)-N-(1-(4-chloro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-(difluoromethyl)-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-bromo-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-cyclopropyl-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,6-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(3,4-difluorophenyl)-3-hydroxybutanamide,
(R)-3-(2-bromo-6-fluorophenyl)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl) cyclopropyl)-3-hydroxybutanamide,
(R)-N-(1-(2-chloro-6-(2,2,2-trifluoroethoxy)pyridin-4-yl)cyclopropyl)-3-(2,6-difluorophenyl) -3-hydroxybutanamide,
(R)-3-(2,4-difluorophenyl)-N-(1-(2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl) cyclopropyl)-3-hydroxybutanamide,
(R)-N-(1-(4,6-dichloropyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(4-chloro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-3-(2,6-difluorophenyl)-3-hydroxy-N-(1-(6-((2,2,2-trifluoroethyl) amino) pyridin-2-yl)cyclopropyl)butanamide,
(R)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(3-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(R)- N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,6-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(4-chloro-6-(neopentylamino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide),
(R)-N-(1-(6-((cyclopropylmethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,

(R)-N-(1-(4-chloro-6-(isopropylamino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(2-chloro-6-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(6-chloropyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(4-chloro-6-((2,2,2-trifluoroethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-3-(2,6-difluorophenyl)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)butanamide,
(R)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)butanamide,
(R)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(6-(trifluoromethyl)pyridin-2-yl)cyclopropyl)butanamide,
(R)-N-(1-(3-(difluoromethyl)-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(4-fluorophenyl)-3-hydroxybutanamide,
(R)-3-(4-fluorophenyl)-N-(1-(2-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxybutanamide,
(R)-N-(1-(6-chloro-4-((2,2,2-trifluoroethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(6-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(R)-N-(1-(4-chloro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-hydroxy-3-(1-methyl-1H-indol-4-yl)butanamide,
(R)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(2-((2,2,2-trifluoroethyl)amino)pyrimidin-4-yl)cyclopropyl)butanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-dimethylthiazol-5-yl)-3-hydroxybutanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxy-3-(4-methylthiazol-2-yl)butanamide,
(R)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(5-chlorothiazol-2-yl)-3-hydroxybutanamide,
(R)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4,6-trifluorophenyl)butanamide,

(S)-3-(6-chloropyridin-3-yl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclo-propyl)butanamide,
(S)-3-(5-fluoropyridin-2-yl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-butanamide,
(S)-3-hydroxy-3-(2-methoxypyridin-4-yl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclo-propyl)butanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-3-(2,4-difluorophenyl)-N-(1-(4-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxybutanamide,
(S)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-butanamide,
(S)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(trifluoromethoxy)phenyl)cyclopropyl) butanamide,
(S)-3-(4-fluorophenyl)-3-hydroxy-N-(1-(2-(2,2,2-trifluoroethoxy)pyridin-4-yl)cyclopropyl)butanamide,
(S)-3-hydroxy-3-(p-tolyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)butanamide,
(S)-3-(4-cyanophenyl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-butanamide,
(S)-3-(2,4-difluorophenyl)-N-(1-(2-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxybutanamide,
(S)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(4-methyl-3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(S)-N-(1-(3-chloro-5-(difluoromethyl)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-3-(3,5-difluorophenyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-butanamide,
(S)-4,4,4-trifluoro-3-(4-fluorophenyl)-3-hydroxy-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(S)-N-(1-(3-bromophenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-cyano-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(4-fluorophenyl)-3-hydroxybutanamide,

(S)-(3-(2,4-difluorophenyl)-N-(1-(3-fluoro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxybutanamide,
(S)-N-(1-(4-chloro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-(difluoromethyl)-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-bromo-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-cyclopropyl-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,6-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(3,4-difluorophenyl)-3-hydroxybutanamide,
(S)-3-(2-bromo-6-fluorophenyl)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl) cyclopropyl)-3-hydroxybutanamide,
(S)-N-(1-(2-chloro-6-(2,2,2-trifluoroethoxy)pyridin-4-yl)cyclopropyl)-3-(2,6-difluorophenyl) -3-hydroxybutanamide,
(S)-3-(2,4-difluorophenyl)-N-(1-(2-fluoro-5-(2,2,2-trifluoroethoxy)phenyl) cyclopropyl)-3-hydroxybutanamide,
(S)-N-(1-(4,6-dichloropyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(4-chloro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-3-(2,6-difluorophenyl)-3-hydroxy-N-(1-(6-((2,2,2-trifluoroethyl) amino) pyridin-2-yl)cyclopropyl)butanamide,
(S)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(3-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-cyclopropyl)butanamide,
(S)- N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,6-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(4-chloro-6-(neopentylamino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide),
(S)-N-(1-(6-((cyclopropylmethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,

(S)-N-(1-(4-chloro-6-(isopropylamino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(2-chloro-6-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(6-chloropyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(4-chloro-6-((2,2,2-trifluoroethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-3-(2,6-difluorophenyl)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)butanamide,
(S)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)butanamide,
(S)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(6-(trifluoromethyl)pyridin-2-yl)cyclopropyl)butanamide,
(S)-N-(1-(3-(difluoromethyl)-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(4-fluorophenyl)-3-hydroxybutanamide,
(S)-3-(4-fluorophenyl)-N-(1-(2-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxybutanamide,
(S)-N-(1-(6-chloro-4-((2,2,2-trifluoroethyl)amino)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(6-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4-difluorophenyl)-3-hydroxybutanamide,
(S)-N-(1-(4-chloro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-hydroxy-3-(1-methyl-1H-indol-4-yl)butanamide,
(S)-3-(2,4-difluorophenyl)-3-hydroxy-N-(1-(2-((2,2,2-trifluoroethyl)amino)pyrimidin-4-yl)cyclopropyl)butanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(2,4-dimethylthiazol-5-yl)-3-hydroxybutanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-hydroxy-3-(4-methylthiazol-2-yl)butanamide,
(S)-N-(1-(3-chloro-5-(2,2,2-trifluoroethoxy)phenyl)cyclopropyl)-3-(5-chlorothiazol-2-yl)-3-hydroxybutanamide or
(S)-3-hydroxy-N-(1-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl)cyclopropyl)-3-(2,4,6-trifluorophenyl)butanamide

or a pharmaceutically acceptable salt thereof.

14. The compound according to any one of the preceding claims, wherein the compound is able to produce an increase in the activity of the $K_v7.2/K_v7.3$ heteromeric channel with an EC_{50} of less than 20 μM, as measured by a thallium ion (Tl+) influx assay.

15. Use of a compound according to any of the preceding claims in the manufacture of a medicament for increasing the activity of a $K_v7.2/K_v7.3$ heteromeric channel in a subject, or the treatment, prevention or alleviation of epilepsy or pain in a subject.

16. A compound according to any one of claims 1 to 14 for use in therapy.